Biotechnology Some 34% of surveyed US neurologists have prescribed French drug major Sanofi (Euronext: SAN) subsidiary Genzyme's Aubagio (teriflunomide), to at least one of their multiple sclerosis (MS) patients at three months post-launch, a significant increase in trial rate from one month post-launch (16%), according to a new report from BioTrends Research, a unit of health care advisory firm Decision Resources. 7 March 2013